Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kamux’s Shareholders’ Nomination Board Has Been Appointed

Kamux Corporation    Stock Exchange Release    30 September 2020 at 12:00 Kamux’s Shareholders’ Nomination Board Has Been Appointed Kamux’s Shareholders’ Nomination Board has been established according to the resolution of the Annual General Meeting held on April 21, 2020. The purpose of the Shareholders’ Nomination Board is to annually prepare and present to the Annual General Meeting, and to Extraordinary General Meeting when necessary, the proposals for the composition of the Board of Directors (the amount of members and the persons) and for the renumeration in accordance with the

Vestas wins 184 MW order in USA and secures 10 GW of order intake in 2020

News release from Vestas-American Wind TechnologyPortland, 30 September 2020 Vestas has received a 184 MW order of V120-2.2 MW and V110-2.2 MW wind turbines in the USA, which takes Vestas’ order intake in 2020 across the 10 GW mark before entering the fourth quarter.The order includes supply and commissioning of the turbines as well as a multi-year service agreement. Turbine delivery is scheduled to begin the second quarter of 2021, with commissioning scheduled for the fourth quarter of 2021. The customer and project are undisclosed per the customer’s request.For more

TR-1: S tandard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS[][][][][][][]NOTIFICATION OFMAJOR HOLDINGS(tobe sent to therelevant issuerandto the FCA inMicrosoft Wordformatif possible)[i] 1a. Identity of Faron Pharmaceuticalsthe issuer or the Ltdunderlying issuerof existingsharesto which votingrights areattached[ii]:1b. Pleaseindicate if theissuer isa non-UK issuer (please markwithan “X” ifappropriate)Non-UK issuer X2. Reason for thenotification(

Invitation to Ascelia Pharma’s virtual Capital Markets Day

Ascelia Pharma AB (publ) (ticker: ACE) hereby invites analysts, investors and media to its virtual Capital Markets Day on Wednesday October 21, 2020. Focus of the day will be on Mangoral market opportunity and preparations for commercialization.Live Q&A webcastThe virtual event consists of presentations from Ascelia Pharma executives followed by a live Q&A webcast. The presentations will be available on Ascelia Pharma’s website www.ascelia.com on October 21 at 08:00 a.m. CET. The livestreamed Q&A webcast with will take place on October 21 from 14:00-15:00 CET. A recording of the Q&A

New number of shares and votes in Nolato AB (publ)

The incentive programme for senior executives that was introduced at the extraordinary general meeting of 5 December 2016 entitles holders of Series 2 share warrants to subscribe for new shares in the company between 1 May and 15 December 2020. In September a total of 153,000 Class B shares were subscribed for through the exercise of share warrants received from the incentive programme. Prior to the issue of the new shares there were 26,581,308 shares and 51,415,908 votes in the company. At 30 September 2020 there are a total of 26,734,308 shares and 51,568,908 votes in the company. These

Vestas receives 185 MW order in the USA

News release from Vestas-American Wind TechnologyPortland, 30 September 2020 Vestas has received a 185 MW order of V150-4.2 MW turbines in 4.3 MW Power Optimised Mode for a wind project in the USA.  The order includes supply and commissioning of the turbines as well as a 20-year service agreement, designed to ensure optimised performance for the lifetime of the project. Turbine delivery is scheduled for the second quarter of 2021 with commissioning scheduled for the fourth quarter of 2021. “We’re pleased to expand the V150 footprint in the U.S.”, said Austin Schroll, Senior Director

Nordic Nanovector ASA - Tranche 1 share capital increase registered

Oslo, Norway, 30 September 2020 Reference is made to the stock exchange announcement on 23 September 2020 regarding the successful completion of Nordic Nanovector ASA's (OSE: NANO) (the "Company") private placement of new shares (the "Private Placement"). The Private Placement is divided into two tranches, as further explained in the stock exchange announcement on 23 September 2020. The share capital increase pertaining to the 6,850,350 new shares, each with a nominal value of NOK 0.20, to be issued in tranche 1 of the Private Placement (the "Tranche 1 Shares") has been registered in

Offer document regarding GB HoldCo AB's cash offer to the shareholders in Gunnebo Aktiebolag made public

­This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important information" at the end of this press

Report from the Extraordinary General Meeting in Wallenstam AB

Today, on September 30, 2020, an Extraordinary General Meeting was held in Wallenstam AB (publ). The Extraordinary General Meeting resolved, in accordance with the Board of Director’s proposal, to pay a dividend for the 2019 financial year of SEK 0.50 per share. The record day for the payment was set as October 2, 2020 and disbursement from Euroclear Sweden AB is expected to take place on October 7, 2020.

Full patient enrolment in Phase IIa Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) has reached full patient enrolment in its Phase IIa menstrual migraine (MM) study. 158 women have been recruited as scheduled at seven test centers across Sweden and Finland despite Covid-19 restrictions. Sepranolone, the endogenous compound being tested for MM, is the first therapy to focus exclusively on menstrual migraine. MM affects 50 million women worldwide and is resistant to standard migraine treatments including the new CGRP antibodies. Topline results are expected in Q2 2021.In the Spring of 2020, four of Asarina Pharma’s seven test

AFRY to design a chlorine dioxide plant for Metsä Fibre's bioproduct mill

Metsä Fibre Oy, part of the Metsä Group, and AFRY have entered into a preliminary agreement for the engineering, project management and site services of the chlorine dioxide plant at the Kemi bioproduct mill in Finland. The project is a continuation of AFRY's previous basic design of the chlorine dioxide plant.The chlorine dioxide plant will be implemented by using the EPCM project model, in which the Canadian based company ERCO is responsible for process technology solutions and supply of the main process equipment. The salt fraction generated in the production of chlorine dioxide will be

Metsä Fibre signed a preliminary agreement with ERCO and AFRY on the chlorine dioxide plant of the Kemi bioproduct mill

Metsä Fibre press release 30.9.2020Metsä Fibre, part of Metsä Group, and ERCO Worldwide have signed a preliminary agreement on the delivery of process technology and main equipment for the chlorine dioxide plant of the Kemi bioproduct mill. The process technology will be based on ERCO’s latest R8/R10 technology, which is in use, for example, at the chlorine dioxide plant of Metsä Fibre’s pulp mill in Joutseno. The salt fraction generated in the production of chlorine dioxide will be used in the closed chemical cycle of the bioproduct mill, contributing to our high material efficiency.

Number of shares and votes in Calliditas Therapeutics

During September, Calliditas Therapeutics AB (publ) has allotted 111,250 common shares within the company’s warrant program issued in 2017. Thus, as of September 30, 2020, the number of shares and votes in the company amounts to 49,941,584. For further information, please contact: Mikael Widell, Investor relations Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for

Establishment of Nomination Committee in I.A.R. Systems Group AB

Stockholm, Sweden—September 30, 2020— In accordance with the Annual General Meeting April 29, 2020, the Nomination Committee is composed to include Jonas Eixmann appointed by Andra AP-fonden, Ossian Ekdahl appointed by Första AP-fonden and Evert Carlsson appointed by Swedbank Robur Fonder. Jonas Eixmann was appointed Chairman.The task of the nominating committee is to propose the Chairman at the annual general meeting 2021, Chairman and other members of the board as well as suggesting remuneration and other compensation for each of the board members. The Nominating Committee shall also

Avidly Plc has acquired the minority shares of its subsidiary Avidly Media Oy

Avidly Plc has acquired the minority shares of its subsidiary Avidly Media Oy Avidly Plc, company announcement, 30 September 2020 at 11:00 a.m. EET Avidly Plc (”Company”) has acquired 125 minority shares of Avidly Media Oy, a subsidiary belonging to Avidly group of companies, through a share deal through which Avidly Media Oy became a wholly-owned subsidiary of the Company. Prior to the share deal the Company owned 95% of Avidly Media Oy’s shares. The shares that were subject to the share deal were acquired from Avidly Media Oy’s managing director. The purchase price of EUR 19,024.

Invitation: Press and analyst conference

Holmen’s interim report for January–September 2020 will be published at lunchtime on Wednesday 21 October. In view of this, you are invited to watch the online broadcast of our press and analyst conference on the same day at 14.30 CEST. Time: 21 October at 14.30 CESTOnline broadcast: www.holmen.com/reports Holmen President and CEO Henrik Sjölund, together with CFO Anders Jernhall, will present and comment on the report. The presentation will be held in English. You may also participate in the conference by telephone, by calling: +46 8 505 583 54 (within Sweden)+44 333 300

Lantmännen nominated for the Employer Branding Company of the Year Award for 2021

Lantmännen is one of the companies nominated for the 2021 Employer Branding Company of the Year Award, presented annually by Universum. Lantmännen has been nominated for its strong corporate culture and because the company has successfully portrayed a broad and inspiring image of itself as a company that offers plenty of challenges for talented individuals.Lantmännen has a long-term employee strategy in place that has been continuously developed in recent years to further strengthen the firmly established employee engagement, and to attract more talented co-workers. This work has now been

Read original

Vestas’ secures new auction win in Italy

News release from Vestas MediterraneanMadrid, 30 September 2020 Vestas has secured a 28 MW order from the AM Energie Rinnovabili for the Serra del Vento project, located in the Palermo province. The order includes the supply and installation of eight V136-3.45 MW wind turbines as well as a 20-year Active Output Management 5000 (AOM 5000) service agreement. This order adds to the more than 1.1 GW of contracts signed by Vestas in Italy’s auction system, which showcases the company’s ability to support customers in submitting winning auction bids. The order also reinforces Vestas’

BioStock: Cereno Scientific is shifting gears

When the US FDA granted the Orphan Drug Designation for CS1 in Pulmonary Arterial Hypertension, Cereno Scientific opened a door to new possibilities and attractive opportunities. Now, the company has decided to refocus its development efforts for its lead candidate CS1 to rare disease PAH, which they say will optimize the opportunities for the company as well as its shareholders. As a confirmation of the investor community’s high hopes for the project, Cereno Scientific also announced that they have raised 60 million SEK in a directed share issue.Read the full article at biostock.se:

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 59 - 30 SEPTEMBER 2020 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, Motortramp A/S continuously sells shares pro rata and the market is to be informed accordingly – see the attached file. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451Anne-Louise Dam-Rasmussen, Head of Communications, tel.: +45 3273 0624

Change in number of shares and votes in Addtech AB

The total number of shares and votes in Addtech AB, reg. no 556302-9726 (“Addtech”) has changed in September 2020 consequent upon that the number of A-shares have increased with 9,664,308 A-shares and the number of B-shares have increased with 194,931,180 B-shares upon the Annual General Meeting in Addtech held on 28 August 2020 resolving on a share split (4:1). After the share split the total number of shares and votes in Addtech as per 30 September 2020 amounts to 272,793,984 shares and 388,765,680 votes, respectively. 12,885,744 of these shares are class A shares, representing 128,857,

Diös Nomination Committee for the AGM 2021

According to the resolution at the 2020 Annual General Meeting, the Nomination Committee shall comprise the Chairman of the Board and representatives of the four largest shareholders and be published no later than six months before the Annual General Meeting. In accordance with the decision, the following Nomination Committee has been formed: · Bob Persson, Chairman of the Board and representative for AB Persson Invest. · Stefan Nilsson, representative for Pensionskassan SHB Försäkringsförening. · Carl Engström, representative for Nordstjernan AB. · Magnus Swärdh,

A total of SEK 541 million is granted to 18 research projects in Sweden

Studies of the Arctic climate in a year-round perspective, alternatives to quantum computers and studies of nerve cells to understand changed emotion and cognition with autism, are what some of the 18 projects that receive funding from Knut and Alice Wallenberg Foundation are about.Knut and Alice Wallenberg Foundation has granted a total of SEK 541 million to 18 outstanding basic research projects in medicine, science and technology that are considered to have the opportunity to lead to future scientific breakthroughs. “What is extra gratifying about this round is that 60 percent of the

Change in number of shares and votes in Hufvudstaden

When the total number of shares or votes in the company changes, the company shall by law publish information regarding the change. At the 2001 Annual General Meeting, a share conversion clause was added to Hufvudstaden’s articles of association. Shareholders have the right at any time to request conversion of series C shares to series A shares. During the month of September 2020, 49 series C shares were converted to series A shares. Through the share conversion, the total number of votes in the company has decreased from 1,030,210,427 to 1,030,205,576 votes. The total number of

There are no items matching the current filter
There are no more items matching the current filter
Back to top